Aerie Pharmaceuticals Inc.'s claims about the efficacy of its triple-acting glaucoma drug, Rhopressa (netarsudil), earned uncomplicated support from FDA briefing docs published ahead of the agency's Friday Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) meeting, sending company shares (NASDAQ:AERI) climbing 16.2 percent to $64.30 on Wednesday as the company took another substantive step toward an anticipated Feb. 28 approval or earlier.